Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is. We appreciate Sarepta’s efforts and dedication […]
The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Read the full newsletter here.
Organizations to provide financial support for 50 Duchenne families to travel to Southern California for the CureDuchenne 2019 FUTURES national conference NEWPORT BEACH, Calif. (July 1, 2019) — CureDuchenne, the […]
Pfizer made their first public disclosure on early data from their open-label Phase 1 microdystrophin gene therapy trial for the treatment of Duchenne. The program was obtained from Pfizer’s acquisition […]
We are excited to report the progress of CureDuchenne’s Gene Therapy Initiative. From our investment, as early as 2010, in Nationwide Children’s permanent duplication2 skipping program, to what has become […]
In 2003 when my son Hawken was diagnosed with Duchenne people were not contemplating a cure. To find a pharmaceutical company working on Duchenne was like finding a needle in […]
Deal will accelerate drug development for Duchenne muscular dystrophy, a rare disease that affects 300,000 boys and young men worldwide June 06, 2019 07:11 PM Eastern Daylight Time NEWPORT BEACH, […]
NEWPORT BEACH, CA (April 24, 2019) — Austin’s finest recently came together for Champions to CureDuchenne, an annual charity event that benefits CureDuchenne, a national nonprofit that funds research to […]
WAVE Open Letter to Community
